JP5323682B2 - コンパートメント症候群の治療における使用のための抗分泌性タンパク質 - Google Patents

コンパートメント症候群の治療における使用のための抗分泌性タンパク質 Download PDF

Info

Publication number
JP5323682B2
JP5323682B2 JP2009507631A JP2009507631A JP5323682B2 JP 5323682 B2 JP5323682 B2 JP 5323682B2 JP 2009507631 A JP2009507631 A JP 2009507631A JP 2009507631 A JP2009507631 A JP 2009507631A JP 5323682 B2 JP5323682 B2 JP 5323682B2
Authority
JP
Japan
Prior art keywords
antisecretory
use according
caused
syndrome
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009507631A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009535328A5 (enExample
JP2009535328A (ja
Inventor
ハンス−アーネ・ハンソン
ステファン・ランゲ
エヴァ・イェニシェ
トーマス・ベルイストレム
Original Assignee
ラントメネン・アーエス−ファクトール・アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラントメネン・アーエス−ファクトール・アーベー filed Critical ラントメネン・アーエス−ファクトール・アーベー
Publication of JP2009535328A publication Critical patent/JP2009535328A/ja
Publication of JP2009535328A5 publication Critical patent/JP2009535328A5/ja
Application granted granted Critical
Publication of JP5323682B2 publication Critical patent/JP5323682B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
JP2009507631A 2006-04-27 2007-04-27 コンパートメント症候群の治療における使用のための抗分泌性タンパク質 Active JP5323682B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0600933-6 2006-04-27
SE0600933 2006-04-27
PCT/SE2007/000413 WO2007126363A2 (en) 2006-04-27 2007-04-27 Antisecretory protein for use in the treatment of compartment syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010245989A Division JP5285043B2 (ja) 2006-04-27 2010-11-02 コンパートメント症候群の治療における使用のための抗分泌性タンパク質

Publications (3)

Publication Number Publication Date
JP2009535328A JP2009535328A (ja) 2009-10-01
JP2009535328A5 JP2009535328A5 (enExample) 2010-06-17
JP5323682B2 true JP5323682B2 (ja) 2013-10-23

Family

ID=38655929

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009507631A Active JP5323682B2 (ja) 2006-04-27 2007-04-27 コンパートメント症候群の治療における使用のための抗分泌性タンパク質
JP2010245989A Active JP5285043B2 (ja) 2006-04-27 2010-11-02 コンパートメント症候群の治療における使用のための抗分泌性タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010245989A Active JP5285043B2 (ja) 2006-04-27 2010-11-02 コンパートメント症候群の治療における使用のための抗分泌性タンパク質

Country Status (19)

Country Link
US (2) US8309513B2 (enExample)
EP (2) EP2363140B1 (enExample)
JP (2) JP5323682B2 (enExample)
KR (3) KR101805973B1 (enExample)
CN (3) CN104689299B (enExample)
AT (1) ATE526031T1 (enExample)
AU (1) AU2007244003B2 (enExample)
BR (2) BRPI0710794A2 (enExample)
CA (1) CA2650589C (enExample)
DK (3) DK2037950T3 (enExample)
ES (3) ES2472737T3 (enExample)
IL (1) IL194774A (enExample)
MX (1) MX2008013774A (enExample)
NZ (2) NZ572256A (enExample)
PL (2) PL2040734T3 (enExample)
RU (2) RU2457853C2 (enExample)
SG (1) SG171601A1 (enExample)
WO (1) WO2007126363A2 (enExample)
ZA (2) ZA200809114B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014111623A (ja) * 2006-04-27 2014-06-19 Lantmaennen As-Faktor Ab 脂質ラフトの調節

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG171602A1 (en) * 2006-04-27 2011-06-29 Lantmaennen As Faktor Ab Use of antisecretory factors for treating intraocular hypertension
PL2040734T3 (pl) 2006-04-27 2012-04-30 Lantmaennen As Faktor Ab Białko przeciwwydzielnicze do zastosowania w leczeniu zespołu przedziału
US9962424B2 (en) 2007-04-27 2018-05-08 Lantmännen As-Faktor Ab Use of antisecretory factors (AF) for optimizing cellular uptake
US8901083B2 (en) 2008-11-25 2014-12-02 Temple University Administration of angiocidin for the treatment of leukemia
JP5820277B2 (ja) * 2009-02-11 2015-11-24 ラントメネン・アーエス−ファクトール・アーベー 細胞取込を最適化するための抗分泌性因子（ａｆ）の使用
WO2017009004A1 (en) 2015-07-10 2017-01-19 Lantmännen As-Faktor Ab Process for producing egg yolk with high content of af-16
US11407796B2 (en) 2016-07-18 2022-08-09 Lantmännen As-Faktor Ab Antisecretory factor 17
WO2020002464A1 (en) 2018-06-28 2020-01-02 Lantmännen Medical Ab Antisecretory factor for use in treatment and/or prevention of acute respiratory failure
WO2020065091A1 (en) 2018-09-28 2020-04-02 Lantmännen Functional Foods Ab A consumable product comprising malted wheat
CN112770643A (zh) 2018-09-28 2021-05-07 兰特门内保健食品公司 包含麦芽化脱壳燕麦的可消耗产品
EP4125984A1 (en) 2020-03-26 2023-02-08 Lantmännen Functional Foods AB A consumable product comprising malted cereals for promoting recovery at physical activity
WO2026099453A1 (en) * 2024-11-07 2026-05-15 Lantmännen Medical Ab Af-16 or af-17 for acute treatment of brain oedema in patients with traumatic brain injury

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH682716A5 (de) * 1992-01-13 1993-11-15 Christian Fricker Benzo-Pyrone und/oder Dobesilat-Calcium enthaltende pharmazeutische Zusammensetzung.
US5585401A (en) 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
SE508609C2 (sv) 1995-08-24 1998-10-19 Rural Patent Svenska Ab Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
SE9604251L (sv) 1996-11-20 1997-12-22 Svenska Lantmaennen Riksfoerbu Födoämne som vid förtäring inducerar antisekretoriska proteiner
SE513496C2 (sv) * 1998-12-17 2000-09-18 Rural Patent Svenska Ab NASP-berikad äggula samt dess användning
US7662169B2 (en) * 2000-09-05 2010-02-16 Wittmann Dietmar H Prosthesis and method for lowering abdominal pressure
GB0322645D0 (en) * 2003-09-26 2003-10-29 Melacure Therapeutics Ab Use of antisecretory factor peptides
KR20090037992A (ko) 2006-04-27 2009-04-17 란트만넨 아스-팍토르 아베 항분비 단백질의 추가적 의학 용도
PL2040734T3 (pl) 2006-04-27 2012-04-30 Lantmaennen As Faktor Ab Białko przeciwwydzielnicze do zastosowania w leczeniu zespołu przedziału
WO2009052478A1 (en) * 2007-10-19 2009-04-23 Trustees Of Boston University Metabolic and cardioprotection by the myokine follistatin-like 1 polypeptide

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014111623A (ja) * 2006-04-27 2014-06-19 Lantmaennen As-Faktor Ab 脂質ラフトの調節

Also Published As

Publication number Publication date
EP2363140B1 (en) 2016-12-14
DK2363140T3 (en) 2017-03-06
AU2007244003A1 (en) 2007-11-08
KR20090045148A (ko) 2009-05-07
NZ572256A (en) 2012-02-24
US20110305773A1 (en) 2011-12-15
ES2472737T3 (es) 2014-07-02
CN101437533A (zh) 2009-05-20
WO2007126363A3 (en) 2008-03-13
DK2037950T3 (da) 2014-06-30
RU2008146731A (ru) 2010-06-10
ES2374712T3 (es) 2012-02-21
NZ572257A (en) 2011-10-28
JP2011032284A (ja) 2011-02-17
MX2008013774A (es) 2009-02-03
JP2009535328A (ja) 2009-10-01
PL2363140T3 (pl) 2017-05-31
JP5285043B2 (ja) 2013-09-11
SG171601A1 (en) 2011-06-29
US8309513B2 (en) 2012-11-13
CA2650589C (en) 2017-06-13
EP2363140A1 (en) 2011-09-07
DK2040734T3 (da) 2012-01-23
AU2007244003B2 (en) 2012-08-02
BRPI0710794A2 (pt) 2011-06-21
CA2650589A1 (en) 2007-11-08
KR101805973B1 (ko) 2017-12-06
PL2040734T3 (pl) 2012-04-30
EP2040734A2 (en) 2009-04-01
CN104689299A (zh) 2015-06-10
US8389468B2 (en) 2013-03-05
CN101460187B (zh) 2014-11-05
BRPI0710858A2 (pt) 2011-05-17
CN101437533B (zh) 2016-10-12
ZA200809114B (en) 2009-06-24
ES2615515T3 (es) 2017-06-07
KR20140123601A (ko) 2014-10-22
US20090185982A1 (en) 2009-07-23
WO2007126363A8 (en) 2008-10-30
ATE526031T1 (de) 2011-10-15
EP2040734B1 (en) 2011-09-28
ZA200809116B (en) 2009-07-29
WO2007126363A2 (en) 2007-11-08
CN104689299B (zh) 2020-02-21
IL194774A (en) 2015-07-30
KR20140141729A (ko) 2014-12-10
CN101460187A (zh) 2009-06-17
IL194774A0 (en) 2011-08-01
RU2008146734A (ru) 2010-06-10
RU2457853C2 (ru) 2012-08-10
HK1131738A1 (en) 2010-02-05
KR101757523B1 (ko) 2017-07-12
RU2465914C2 (ru) 2012-11-10

Similar Documents

Publication Publication Date Title
JP5285043B2 (ja) コンパートメント症候群の治療における使用のための抗分泌性タンパク質
JP6063401B2 (ja) 脂質ラフトの調節
HK1131738B (en) Antisecretory protein for use in the treatment of compartment syndrome
HK1156529A (en) Antisecretory protein for use in the treatment of compartiment syndrome
HK1156529B (en) Antisecretory protein for use in the treatment of compartiment syndrome
HK1128237B (en) Further medical uses of antisecretory protein

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121003

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130522

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130530

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130702

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130717

R150 Certificate of patent or registration of utility model

Ref document number: 5323682

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250